Fair Game: Valeant’s High-Price Drug Strategy

Saturday, October 3, 2015 - 08:30 in Mathematics & Economics

Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company’s price increases.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net